| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Glioblastoma | 47 | 2021 | 219 | 13.000 |
Why?
|
| Apoptosis | 89 | 2021 | 1641 | 11.190 |
Why?
|
| Brain Neoplasms | 26 | 2021 | 371 | 6.710 |
Why?
|
| Neuroblastoma | 21 | 2013 | 109 | 5.990 |
Why?
|
| Antineoplastic Agents | 23 | 2020 | 1070 | 4.710 |
Why?
|
| Calpain | 50 | 2020 | 205 | 4.610 |
Why?
|
| Telomerase | 14 | 2019 | 85 | 3.680 |
Why?
|
| Cell Line, Tumor | 54 | 2021 | 1851 | 3.600 |
Why?
|
| Autophagy | 11 | 2021 | 208 | 3.350 |
Why?
|
| Fenretinide | 9 | 2020 | 26 | 3.270 |
Why?
|
| MicroRNAs | 10 | 2019 | 447 | 3.190 |
Why?
|
| Neuroprotective Agents | 25 | 2020 | 317 | 3.040 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 30 | 2020 | 174 | 2.970 |
Why?
|
| Paclitaxel | 10 | 2012 | 140 | 2.730 |
Why?
|
| Apigenin | 6 | 2013 | 10 | 2.480 |
Why?
|
| Cell Survival | 32 | 2020 | 901 | 2.430 |
Why?
|
| Estrogens | 19 | 2022 | 173 | 2.430 |
Why?
|
| Interferon-gamma | 14 | 2011 | 241 | 2.370 |
Why?
|
| Cell Differentiation | 14 | 2020 | 1034 | 2.250 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 8 | 2016 | 468 | 2.180 |
Why?
|
| Spinal Cord Injuries | 21 | 2022 | 551 | 2.110 |
Why?
|
| Caspases | 17 | 2012 | 194 | 1.860 |
Why?
|
| Tretinoin | 10 | 2016 | 92 | 1.850 |
Why?
|
| Retinoids | 7 | 2019 | 122 | 1.830 |
Why?
|
| Cell Cycle | 8 | 2011 | 312 | 1.730 |
Why?
|
| Genistein | 5 | 2013 | 26 | 1.580 |
Why?
|
| Signal Transduction | 25 | 2016 | 2689 | 1.550 |
Why?
|
| Apoptosis Regulatory Proteins | 11 | 2016 | 100 | 1.520 |
Why?
|
| bcl-2-Associated X Protein | 24 | 2020 | 111 | 1.510 |
Why?
|
| Motor Neurons | 10 | 2020 | 98 | 1.470 |
Why?
|
| Transfection | 12 | 2016 | 782 | 1.460 |
Why?
|
| Inhibitor of Apoptosis Proteins | 7 | 2016 | 40 | 1.400 |
Why?
|
| Drug Synergism | 10 | 2020 | 260 | 1.370 |
Why?
|
| RNA, Small Interfering | 12 | 2013 | 434 | 1.320 |
Why?
|
| Animals | 87 | 2022 | 20881 | 1.310 |
Why?
|
| Catechin | 4 | 2012 | 26 | 1.280 |
Why?
|
| Down-Regulation | 13 | 2013 | 447 | 1.250 |
Why?
|
| Humans | 99 | 2021 | 68618 | 1.200 |
Why?
|
| Rats | 45 | 2022 | 5300 | 1.190 |
Why?
|
| Anticarcinogenic Agents | 4 | 2011 | 52 | 1.170 |
Why?
|
| Proto-Oncogene Proteins c-myc | 4 | 2013 | 90 | 1.160 |
Why?
|
| Blotting, Western | 27 | 2016 | 954 | 1.160 |
Why?
|
| Cell Movement | 8 | 2020 | 630 | 1.150 |
Why?
|
| Mitochondria | 15 | 2013 | 643 | 1.110 |
Why?
|
| Angiogenesis Inhibitors | 3 | 2020 | 64 | 1.100 |
Why?
|
| Gene Knockdown Techniques | 7 | 2016 | 196 | 1.100 |
Why?
|
| Dipeptides | 15 | 2020 | 89 | 1.100 |
Why?
|
| Caspase 3 | 19 | 2019 | 233 | 1.100 |
Why?
|
| Luteolin | 2 | 2016 | 3 | 1.070 |
Why?
|
| Silymarin | 2 | 2016 | 7 | 1.070 |
Why?
|
| Neoplastic Stem Cells | 4 | 2016 | 84 | 1.040 |
Why?
|
| Up-Regulation | 12 | 2013 | 682 | 1.040 |
Why?
|
| Genetic Therapy | 4 | 2021 | 291 | 1.040 |
Why?
|
| Neurons | 16 | 2016 | 881 | 1.040 |
Why?
|
| Garlic | 4 | 2012 | 12 | 1.000 |
Why?
|
| Cysteine Endopeptidases | 4 | 2009 | 39 | 0.990 |
Why?
|
| Curcumin | 3 | 2012 | 23 | 0.980 |
Why?
|
| Astrocytes | 7 | 2010 | 270 | 0.970 |
Why?
|
| Microtubule-Associated Proteins | 4 | 2019 | 114 | 0.970 |
Why?
|
| Cell Proliferation | 10 | 2020 | 1174 | 0.960 |
Why?
|
| Neurodegenerative Diseases | 5 | 2022 | 102 | 0.960 |
Why?
|
| Flavonoids | 4 | 2012 | 109 | 0.940 |
Why?
|
| Multiple Sclerosis | 6 | 2019 | 132 | 0.940 |
Why?
|
| Caspase 8 | 11 | 2016 | 40 | 0.930 |
Why?
|
| Cytochromes c | 13 | 2011 | 75 | 0.870 |
Why?
|
| Peptide Hydrolases | 3 | 2008 | 82 | 0.860 |
Why?
|
| Enzyme Activation | 16 | 2019 | 791 | 0.860 |
Why?
|
| Dose-Response Relationship, Drug | 15 | 2019 | 1745 | 0.850 |
Why?
|
| In Situ Nick-End Labeling | 21 | 2013 | 160 | 0.840 |
Why?
|
| Serine C-Palmitoyltransferase | 2 | 2019 | 17 | 0.840 |
Why?
|
| Spinal Cord | 18 | 2022 | 244 | 0.820 |
Why?
|
| Neovascularization, Pathologic | 4 | 2012 | 183 | 0.810 |
Why?
|
| Antineoplastic Agents, Phytogenic | 5 | 2015 | 88 | 0.810 |
Why?
|
| Proto-Oncogene Proteins c-akt | 6 | 2013 | 331 | 0.800 |
Why?
|
| Cysteine Proteinase Inhibitors | 10 | 2016 | 73 | 0.780 |
Why?
|
| Calcium | 18 | 2012 | 929 | 0.770 |
Why?
|
| Gene Editing | 1 | 2021 | 33 | 0.760 |
Why?
|
| Enzyme Inhibitors | 7 | 2016 | 659 | 0.750 |
Why?
|
| Dacarbazine | 4 | 2016 | 32 | 0.750 |
Why?
|
| Molecular Targeted Therapy | 4 | 2019 | 170 | 0.740 |
Why?
|
| Diosgenin | 1 | 2020 | 2 | 0.740 |
Why?
|
| PTEN Phosphohydrolase | 4 | 2009 | 108 | 0.730 |
Why?
|
| Sphingosine | 2 | 2019 | 315 | 0.720 |
Why?
|
| Allyl Compounds | 4 | 2013 | 29 | 0.710 |
Why?
|
| Nitriles | 4 | 2010 | 68 | 0.710 |
Why?
|
| Neoplasms | 5 | 2019 | 1667 | 0.700 |
Why?
|
| Photochemotherapy | 2 | 2013 | 59 | 0.690 |
Why?
|
| Drug Resistance, Neoplasm | 4 | 2018 | 332 | 0.680 |
Why?
|
| Benzopyrans | 2 | 2009 | 21 | 0.680 |
Why?
|
| Butyric Acid | 1 | 2019 | 4 | 0.670 |
Why?
|
| Quercetin | 1 | 2019 | 16 | 0.670 |
Why?
|
| Nerve Degeneration | 10 | 2012 | 134 | 0.660 |
Why?
|
| Receptors, Estrogen | 4 | 2016 | 142 | 0.660 |
Why?
|
| Nucleic Acid Amplification Techniques | 1 | 2019 | 21 | 0.650 |
Why?
|
| Mice, Nude | 7 | 2016 | 294 | 0.650 |
Why?
|
| NF-kappa B | 10 | 2012 | 432 | 0.640 |
Why?
|
| Gene Expression Regulation, Neoplastic | 7 | 2013 | 756 | 0.640 |
Why?
|
| Telomere | 1 | 2019 | 59 | 0.640 |
Why?
|
| Encephalomyelitis, Autoimmune, Experimental | 9 | 2017 | 133 | 0.630 |
Why?
|
| Ceramides | 2 | 2019 | 578 | 0.630 |
Why?
|
| Cell Death | 12 | 2018 | 329 | 0.590 |
Why?
|
| Dexamethasone | 3 | 2008 | 150 | 0.580 |
Why?
|
| Alzheimer Disease | 2 | 2016 | 565 | 0.580 |
Why?
|
| Neuroprotection | 2 | 2022 | 28 | 0.580 |
Why?
|
| DNA Fragmentation | 12 | 2009 | 85 | 0.570 |
Why?
|
| Proanthocyanidins | 1 | 2016 | 4 | 0.560 |
Why?
|
| Glycoproteins | 5 | 2020 | 238 | 0.540 |
Why?
|
| Mice | 22 | 2016 | 8474 | 0.540 |
Why?
|
| RNA, Messenger | 9 | 2013 | 1664 | 0.540 |
Why?
|
| Retinoid X Receptors | 1 | 2016 | 26 | 0.530 |
Why?
|
| Glutamic Acid | 6 | 2012 | 332 | 0.530 |
Why?
|
| Leucine | 2 | 2007 | 41 | 0.520 |
Why?
|
| Anthocyanins | 1 | 2015 | 5 | 0.520 |
Why?
|
| Nanocapsules | 1 | 2015 | 10 | 0.520 |
Why?
|
| Adaptor Proteins, Signal Transducing | 1 | 2016 | 214 | 0.500 |
Why?
|
| Sulfides | 4 | 2013 | 43 | 0.490 |
Why?
|
| Xenograft Model Antitumor Assays | 6 | 2016 | 304 | 0.490 |
Why?
|
| Nanotubes, Carbon | 1 | 2015 | 73 | 0.480 |
Why?
|
| Retinal Ganglion Cells | 3 | 2016 | 72 | 0.480 |
Why?
|
| Angiogenesis Inducing Agents | 2 | 2016 | 15 | 0.480 |
Why?
|
| Encephalitis | 1 | 2014 | 43 | 0.480 |
Why?
|
| Carbon | 1 | 2015 | 122 | 0.480 |
Why?
|
| Brain Injuries, Traumatic | 1 | 2016 | 105 | 0.470 |
Why?
|
| Matrix Metalloproteinases | 2 | 2013 | 223 | 0.470 |
Why?
|
| Calcium-Binding Proteins | 6 | 2009 | 114 | 0.470 |
Why?
|
| Protein Kinase Inhibitors | 3 | 2013 | 331 | 0.460 |
Why?
|
| Reactive Oxygen Species | 6 | 2020 | 499 | 0.460 |
Why?
|
| DNA Methylation | 1 | 2015 | 193 | 0.460 |
Why?
|
| Flow Cytometry | 5 | 2016 | 489 | 0.460 |
Why?
|
| BH3 Interacting Domain Death Agonist Protein | 6 | 2011 | 22 | 0.440 |
Why?
|
| Inflammation | 11 | 2022 | 1030 | 0.440 |
Why?
|
| Receptor, Fibroblast Growth Factor, Type 3 | 1 | 2013 | 6 | 0.440 |
Why?
|
| Dihematoporphyrin Ether | 1 | 2013 | 3 | 0.440 |
Why?
|
| Promoter Regions, Genetic | 1 | 2015 | 615 | 0.440 |
Why?
|
| Antineoplastic Agents, Alkylating | 2 | 2021 | 57 | 0.430 |
Why?
|
| Estradiol | 7 | 2022 | 176 | 0.430 |
Why?
|
| Kruppel-Like Transcription Factors | 1 | 2012 | 25 | 0.430 |
Why?
|
| Tea | 1 | 2012 | 23 | 0.430 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p21 | 2 | 2011 | 97 | 0.430 |
Why?
|
| Polyphenols | 1 | 2012 | 34 | 0.420 |
Why?
|
| Optic Neuritis | 4 | 2016 | 26 | 0.410 |
Why?
|
| Cell Line | 11 | 2016 | 1752 | 0.400 |
Why?
|
| Membrane Proteins | 1 | 2016 | 617 | 0.400 |
Why?
|
| bcl-X Protein | 1 | 2011 | 36 | 0.400 |
Why?
|
| Chlorobenzenes | 1 | 2011 | 8 | 0.400 |
Why?
|
| Ethanolamines | 1 | 2011 | 33 | 0.400 |
Why?
|
| Cyclin-Dependent Kinase 2 | 2 | 2011 | 33 | 0.400 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 7 | 2010 | 710 | 0.390 |
Why?
|
| Cathepsins | 2 | 2009 | 37 | 0.390 |
Why?
|
| Immunotherapy | 2 | 2011 | 215 | 0.390 |
Why?
|
| Myelin Basic Protein | 5 | 2016 | 62 | 0.390 |
Why?
|
| Cysteine Proteases | 1 | 2011 | 4 | 0.390 |
Why?
|
| Pyrroles | 2 | 2011 | 83 | 0.380 |
Why?
|
| Oxidative Stress | 4 | 2010 | 718 | 0.380 |
Why?
|
| Indoles | 2 | 2011 | 146 | 0.380 |
Why?
|
| Neoplasm Transplantation | 2 | 2009 | 160 | 0.380 |
Why?
|
| Valproic Acid | 1 | 2011 | 93 | 0.370 |
Why?
|
| Rats, Sprague-Dawley | 16 | 2022 | 2083 | 0.370 |
Why?
|
| Cytosol | 5 | 2008 | 123 | 0.370 |
Why?
|
| Transcription, Genetic | 4 | 2011 | 562 | 0.370 |
Why?
|
| Mutation | 2 | 2021 | 1213 | 0.370 |
Why?
|
| Disulfides | 2 | 2007 | 40 | 0.360 |
Why?
|
| Microglia | 6 | 2016 | 143 | 0.360 |
Why?
|
| Neoplasm Invasiveness | 4 | 2015 | 369 | 0.350 |
Why?
|
| Cyclin D1 | 1 | 2010 | 37 | 0.350 |
Why?
|
| Plant Extracts | 1 | 2011 | 122 | 0.350 |
Why?
|
| Antineoplastic Protocols | 1 | 2009 | 4 | 0.340 |
Why?
|
| Benzenesulfonates | 1 | 2009 | 30 | 0.340 |
Why?
|
| Combined Modality Therapy | 5 | 2016 | 951 | 0.340 |
Why?
|
| Genes, p53 | 1 | 2009 | 41 | 0.330 |
Why?
|
| Brain | 2 | 2019 | 2176 | 0.330 |
Why?
|
| Melatonin | 4 | 2010 | 39 | 0.320 |
Why?
|
| Phospholipases | 1 | 2008 | 12 | 0.320 |
Why?
|
| Acetazolamide | 1 | 2008 | 8 | 0.310 |
Why?
|
| Central Nervous System Diseases | 1 | 2008 | 40 | 0.310 |
Why?
|
| Vascular Endothelial Growth Factor A | 4 | 2011 | 219 | 0.310 |
Why?
|
| Plasmids | 3 | 2013 | 258 | 0.310 |
Why?
|
| Beclin-1 | 2 | 2019 | 11 | 0.310 |
Why?
|
| Methylprednisolone | 2 | 2011 | 99 | 0.300 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2009 | 231 | 0.300 |
Why?
|
| Models, Biological | 6 | 2012 | 981 | 0.300 |
Why?
|
| Central Nervous System Neoplasms | 1 | 2008 | 29 | 0.300 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p27 | 1 | 2007 | 38 | 0.300 |
Why?
|
| Phytic Acid | 1 | 2007 | 4 | 0.300 |
Why?
|
| Pyridines | 1 | 2009 | 261 | 0.300 |
Why?
|
| Transplantation, Heterologous | 1 | 2007 | 122 | 0.290 |
Why?
|
| Aminolevulinic Acid | 1 | 2007 | 5 | 0.290 |
Why?
|
| Fluorescent Antibody Technique | 7 | 2010 | 282 | 0.290 |
Why?
|
| Spectrin | 5 | 2007 | 17 | 0.290 |
Why?
|
| Mitochondrial Proteins | 4 | 2008 | 113 | 0.280 |
Why?
|
| Indomethacin | 1 | 2007 | 107 | 0.280 |
Why?
|
| Mitogen-Activated Protein Kinases | 1 | 2007 | 250 | 0.270 |
Why?
|
| Biological Assay | 3 | 2021 | 88 | 0.270 |
Why?
|
| Axons | 7 | 2022 | 139 | 0.270 |
Why?
|
| Glial Fibrillary Acidic Protein | 5 | 2012 | 92 | 0.270 |
Why?
|
| Patch-Clamp Techniques | 4 | 2016 | 204 | 0.270 |
Why?
|
| Cytokines | 7 | 2012 | 866 | 0.270 |
Why?
|
| Recovery of Function | 4 | 2022 | 506 | 0.270 |
Why?
|
| Caspase Inhibitors | 1 | 2006 | 36 | 0.270 |
Why?
|
| Cells, Cultured | 9 | 2019 | 2673 | 0.260 |
Why?
|
| Poly(ADP-ribose) Polymerases | 2 | 2019 | 39 | 0.260 |
Why?
|
| Caspase 9 | 4 | 2011 | 31 | 0.260 |
Why?
|
| Analysis of Variance | 9 | 2013 | 1040 | 0.260 |
Why?
|
| Gliosis | 6 | 2016 | 51 | 0.260 |
Why?
|
| Recombinant Proteins | 4 | 2007 | 742 | 0.260 |
Why?
|
| Receptors, Cell Surface | 1 | 2006 | 248 | 0.250 |
Why?
|
| Disease Models, Animal | 15 | 2022 | 2550 | 0.250 |
Why?
|
| Membrane Potentials | 5 | 2016 | 200 | 0.250 |
Why?
|
| Graft Survival | 1 | 2007 | 465 | 0.240 |
Why?
|
| Tumor Necrosis Factor-alpha | 4 | 2011 | 626 | 0.240 |
Why?
|
| Membrane Potential, Mitochondrial | 3 | 2016 | 93 | 0.240 |
Why?
|
| Antineoplastic Agents, Hormonal | 1 | 2004 | 99 | 0.230 |
Why?
|
| Sirolimus | 2 | 2016 | 118 | 0.230 |
Why?
|
| Gene Expression | 2 | 2021 | 770 | 0.230 |
Why?
|
| Myelin Proteolipid Protein | 1 | 2003 | 20 | 0.230 |
Why?
|
| Cell Fusion | 3 | 2016 | 23 | 0.220 |
Why?
|
| Myelin Sheath | 3 | 2019 | 115 | 0.220 |
Why?
|
| Parkinson Disease | 4 | 2011 | 272 | 0.210 |
Why?
|
| Ubiquitin-Protein Ligases | 3 | 2008 | 89 | 0.210 |
Why?
|
| Autophagosomes | 2 | 2021 | 6 | 0.210 |
Why?
|
| Gene Expression Regulation, Enzymologic | 3 | 2019 | 282 | 0.210 |
Why?
|
| Gene Expression Regulation | 3 | 2021 | 1293 | 0.210 |
Why?
|
| Fingolimod Hydrochloride | 2 | 2019 | 24 | 0.210 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 3 | 2008 | 216 | 0.210 |
Why?
|
| Estrogens, Conjugated (USP) | 1 | 2022 | 12 | 0.200 |
Why?
|
| Tumor Cells, Cultured | 3 | 2008 | 852 | 0.200 |
Why?
|
| Tumor Stem Cell Assay | 2 | 2013 | 30 | 0.200 |
Why?
|
| Endonucleases | 1 | 2021 | 10 | 0.200 |
Why?
|
| Annexin A5 | 2 | 2013 | 16 | 0.200 |
Why?
|
| Receptors, Melatonin | 2 | 2012 | 8 | 0.190 |
Why?
|
| CRISPR-Cas Systems | 1 | 2021 | 41 | 0.190 |
Why?
|
| Parkinsonian Disorders | 4 | 2008 | 43 | 0.190 |
Why?
|
| Oncogenes | 1 | 2021 | 71 | 0.190 |
Why?
|
| Myoblasts | 2 | 2011 | 22 | 0.190 |
Why?
|
| Gene Transfer Techniques | 1 | 2021 | 173 | 0.180 |
Why?
|
| Nerve Tissue Proteins | 5 | 2012 | 290 | 0.180 |
Why?
|
| Angiogenic Proteins | 1 | 2020 | 5 | 0.180 |
Why?
|
| RNA, Neoplasm | 2 | 2012 | 76 | 0.180 |
Why?
|
| Neoplasm Proteins | 2 | 2016 | 307 | 0.180 |
Why?
|
| Histone Deacetylase 1 | 1 | 2020 | 32 | 0.180 |
Why?
|
| ErbB Receptors | 2 | 2013 | 239 | 0.180 |
Why?
|
| Brain Ischemia | 1 | 2006 | 665 | 0.170 |
Why?
|
| Brain Injuries | 1 | 2003 | 268 | 0.170 |
Why?
|
| Locomotion | 2 | 2022 | 135 | 0.170 |
Why?
|
| Phosphatidylinositol 3-Kinases | 2 | 2013 | 223 | 0.170 |
Why?
|
| Central Nervous System | 2 | 2011 | 107 | 0.170 |
Why?
|
| Carbamates | 2 | 2016 | 41 | 0.170 |
Why?
|
| Matrix Metalloproteinase 2 | 1 | 2020 | 145 | 0.170 |
Why?
|
| Apoptosis Inducing Factor | 2 | 2011 | 10 | 0.170 |
Why?
|
| Matrix Metalloproteinase 9 | 1 | 2020 | 160 | 0.170 |
Why?
|
| Radioactivity | 1 | 2019 | 1 | 0.170 |
Why?
|
| Trypan Blue | 3 | 2007 | 24 | 0.160 |
Why?
|
| HL-60 Cells | 1 | 2019 | 50 | 0.160 |
Why?
|
| Repetitive Sequences, Nucleic Acid | 1 | 2019 | 37 | 0.160 |
Why?
|
| Mitogen-Activated Protein Kinase 8 | 2 | 2010 | 17 | 0.160 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2021 | 446 | 0.160 |
Why?
|
| Sample Size | 1 | 2019 | 79 | 0.160 |
Why?
|
| Radiation-Sensitizing Agents | 1 | 2018 | 35 | 0.160 |
Why?
|
| Phosphorylation | 4 | 2010 | 1200 | 0.160 |
Why?
|
| Isotretinoin | 2 | 2008 | 8 | 0.150 |
Why?
|
| Histone Deacetylase Inhibitors | 1 | 2019 | 116 | 0.150 |
Why?
|
| Drug Interactions | 3 | 2008 | 289 | 0.150 |
Why?
|
| Rats, Inbred Lew | 7 | 2012 | 150 | 0.150 |
Why?
|
| HEK293 Cells | 1 | 2019 | 326 | 0.150 |
Why?
|
| Trauma, Nervous System | 2 | 2009 | 6 | 0.150 |
Why?
|
| Ionomycin | 3 | 2006 | 24 | 0.150 |
Why?
|
| Ionophores | 3 | 2006 | 25 | 0.150 |
Why?
|
| Antigens, Neoplasm | 2 | 2011 | 132 | 0.150 |
Why?
|
| Substantia Nigra | 3 | 2020 | 102 | 0.140 |
Why?
|
| Acridine Orange | 1 | 2016 | 3 | 0.140 |
Why?
|
| Sulfites | 1 | 2016 | 7 | 0.140 |
Why?
|
| Carmustine | 1 | 2016 | 14 | 0.140 |
Why?
|
| Calcium Ionophores | 1 | 2016 | 1 | 0.130 |
Why?
|
| Acrylates | 1 | 2016 | 17 | 0.130 |
Why?
|
| Genetic Heterogeneity | 1 | 2015 | 11 | 0.130 |
Why?
|
| Azides | 1 | 2016 | 56 | 0.130 |
Why?
|
| Cytoprotection | 1 | 2016 | 39 | 0.130 |
Why?
|
| Phosphopyruvate Hydratase | 1 | 2016 | 35 | 0.130 |
Why?
|
| Male | 19 | 2022 | 37321 | 0.130 |
Why?
|
| Azacitidine | 1 | 2015 | 20 | 0.130 |
Why?
|
| Biomarkers, Tumor | 2 | 2011 | 508 | 0.130 |
Why?
|
| Diffusion | 1 | 2015 | 90 | 0.130 |
Why?
|
| Hypoxia | 1 | 2016 | 169 | 0.130 |
Why?
|
| T-Lymphocytes | 2 | 2009 | 597 | 0.130 |
Why?
|
| Workflow | 1 | 2016 | 100 | 0.130 |
Why?
|
| Particle Size | 1 | 2015 | 201 | 0.120 |
Why?
|
| Nervous System Diseases | 1 | 2016 | 142 | 0.120 |
Why?
|
| Precision Medicine | 1 | 2015 | 111 | 0.120 |
Why?
|
| Cell Division | 1 | 2015 | 541 | 0.120 |
Why?
|
| Lysosomes | 2 | 2021 | 136 | 0.120 |
Why?
|
| Colorimetry | 3 | 2010 | 22 | 0.120 |
Why?
|
| Gene Expression Profiling | 1 | 2016 | 498 | 0.120 |
Why?
|
| Polymers | 1 | 2016 | 244 | 0.110 |
Why?
|
| I-kappa B Proteins | 3 | 2010 | 47 | 0.110 |
Why?
|
| Metabolic Diseases | 1 | 2013 | 37 | 0.110 |
Why?
|
| Electrophoresis, Agar Gel | 2 | 2003 | 32 | 0.110 |
Why?
|
| Antibiotics, Antineoplastic | 1 | 2013 | 82 | 0.110 |
Why?
|
| Comet Assay | 1 | 2013 | 11 | 0.110 |
Why?
|
| Motor Activity | 2 | 2022 | 621 | 0.110 |
Why?
|
| Eye | 1 | 2013 | 89 | 0.110 |
Why?
|
| Proto-Oncogene Proteins c-met | 1 | 2013 | 33 | 0.110 |
Why?
|
| Calcium Channels, L-Type | 2 | 2010 | 34 | 0.110 |
Why?
|
| Receptor Protein-Tyrosine Kinases | 1 | 2013 | 100 | 0.110 |
Why?
|
| RNA Interference | 1 | 2013 | 266 | 0.110 |
Why?
|
| Nanoparticles | 1 | 2016 | 254 | 0.110 |
Why?
|
| Th1 Cells | 2 | 2016 | 101 | 0.100 |
Why?
|
| Optic Nerve | 1 | 2012 | 55 | 0.100 |
Why?
|
| Histone Deacetylases | 1 | 2013 | 99 | 0.100 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2013 | 209 | 0.100 |
Why?
|
| Treatment Outcome | 4 | 2012 | 7029 | 0.100 |
Why?
|
| Nitric Oxide Synthase Type II | 2 | 2012 | 201 | 0.100 |
Why?
|
| In Vitro Techniques | 1 | 2013 | 765 | 0.100 |
Why?
|
| Albumin-Bound Paclitaxel | 1 | 2011 | 3 | 0.100 |
Why?
|
| Demyelinating Diseases | 2 | 2009 | 57 | 0.100 |
Why?
|
| Culture Media, Serum-Free | 1 | 2011 | 35 | 0.100 |
Why?
|
| Organelles | 1 | 2011 | 18 | 0.100 |
Why?
|
| Chemotaxis, Leukocyte | 2 | 2009 | 48 | 0.100 |
Why?
|
| Tumor Suppressor Proteins | 2 | 2012 | 194 | 0.100 |
Why?
|
| Microscopy, Fluorescence | 1 | 2012 | 261 | 0.100 |
Why?
|
| Sulfur Compounds | 1 | 2011 | 4 | 0.100 |
Why?
|
| Albumins | 1 | 2011 | 72 | 0.100 |
Why?
|
| Antiparkinson Agents | 1 | 2011 | 34 | 0.100 |
Why?
|
| NF-KappaB Inhibitor alpha | 2 | 2010 | 28 | 0.100 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-2 | 1 | 2011 | 32 | 0.100 |
Why?
|
| Molecular Imaging | 1 | 2011 | 45 | 0.090 |
Why?
|
| E2F1 Transcription Factor | 1 | 2011 | 44 | 0.090 |
Why?
|
| Sodium Channel Blockers | 1 | 2010 | 23 | 0.090 |
Why?
|
| Estrogen Receptor beta | 1 | 2010 | 19 | 0.090 |
Why?
|
| Retinoblastoma Protein | 1 | 2011 | 75 | 0.090 |
Why?
|
| Molecular Weight | 2 | 2012 | 358 | 0.090 |
Why?
|
| Kainic Acid | 1 | 2010 | 44 | 0.090 |
Why?
|
| Ion Channel Gating | 1 | 2010 | 42 | 0.090 |
Why?
|
| 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine | 3 | 2008 | 22 | 0.090 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor Proteins | 1 | 2010 | 1 | 0.090 |
Why?
|
| TNF Receptor-Associated Death Domain Protein | 1 | 2010 | 1 | 0.090 |
Why?
|
| RNA | 1 | 2011 | 171 | 0.090 |
Why?
|
| Base Sequence | 1 | 2012 | 1015 | 0.090 |
Why?
|
| Fas-Associated Death Domain Protein | 1 | 2010 | 7 | 0.090 |
Why?
|
| Epilepsy, Temporal Lobe | 1 | 2012 | 138 | 0.090 |
Why?
|
| Estrogen Receptor alpha | 1 | 2010 | 65 | 0.090 |
Why?
|
| Fas Ligand Protein | 1 | 2010 | 64 | 0.090 |
Why?
|
| Disease Progression | 2 | 2013 | 1038 | 0.090 |
Why?
|
| Subcutaneous Tissue | 1 | 2009 | 6 | 0.090 |
Why?
|
| Myeloid Cell Leukemia Sequence 1 Protein | 1 | 2009 | 19 | 0.090 |
Why?
|
| Cell Culture Techniques | 2 | 2007 | 189 | 0.090 |
Why?
|
| Phenylurea Compounds | 1 | 2009 | 31 | 0.090 |
Why?
|
| Microcirculation | 1 | 2009 | 77 | 0.090 |
Why?
|
| Cell Shape | 1 | 2009 | 37 | 0.090 |
Why?
|
| Immunohistochemistry | 3 | 2007 | 1174 | 0.090 |
Why?
|
| Niacinamide | 1 | 2009 | 31 | 0.090 |
Why?
|
| Seizures | 1 | 2012 | 279 | 0.090 |
Why?
|
| Gene Amplification | 1 | 2009 | 71 | 0.090 |
Why?
|
| Anti-Inflammatory Agents | 3 | 2009 | 234 | 0.090 |
Why?
|
| Drug Therapy, Combination | 1 | 2011 | 649 | 0.080 |
Why?
|
| Inhibitor of Differentiation Protein 2 | 1 | 2009 | 3 | 0.080 |
Why?
|
| Proliferating Cell Nuclear Antigen | 1 | 2009 | 22 | 0.080 |
Why?
|
| Cannabinoid Receptor Modulators | 1 | 2009 | 16 | 0.080 |
Why?
|
| Muscle, Skeletal | 1 | 2012 | 396 | 0.080 |
Why?
|
| Hepatitis, Autoimmune | 1 | 2009 | 22 | 0.080 |
Why?
|
| Kidney | 1 | 2013 | 945 | 0.080 |
Why?
|
| Proto-Oncogene Proteins | 4 | 2004 | 411 | 0.080 |
Why?
|
| Cadherins | 1 | 2009 | 93 | 0.080 |
Why?
|
| Lipopolysaccharides | 1 | 2010 | 455 | 0.080 |
Why?
|
| Aquaporin 1 | 1 | 2008 | 2 | 0.080 |
Why?
|
| Carbonic Anhydrases | 1 | 2008 | 18 | 0.080 |
Why?
|
| Glutathione Transferase | 1 | 2009 | 166 | 0.080 |
Why?
|
| Caspase 1 | 1 | 2008 | 22 | 0.080 |
Why?
|
| Brain Edema | 1 | 2008 | 50 | 0.080 |
Why?
|
| Parkinson Disease, Secondary | 1 | 2007 | 4 | 0.080 |
Why?
|
| Drug Screening Assays, Antitumor | 1 | 2008 | 111 | 0.080 |
Why?
|
| MPTP Poisoning | 1 | 2007 | 10 | 0.080 |
Why?
|
| Proto-Oncogene Proteins c-raf | 1 | 2007 | 20 | 0.070 |
Why?
|
| Mitogen-Activated Protein Kinase Kinases | 1 | 2008 | 82 | 0.070 |
Why?
|
| Amyloid beta-Protein Precursor | 1 | 2008 | 115 | 0.070 |
Why?
|
| Spinal Cord Diseases | 1 | 2007 | 23 | 0.070 |
Why?
|
| Stereotaxic Techniques | 1 | 2007 | 35 | 0.070 |
Why?
|
| Electrophoretic Mobility Shift Assay | 1 | 2007 | 60 | 0.070 |
Why?
|
| Cell Transplantation | 1 | 2007 | 22 | 0.070 |
Why?
|
| Hippocampus | 1 | 2010 | 471 | 0.070 |
Why?
|
| Enzyme Induction | 1 | 2007 | 119 | 0.070 |
Why?
|
| In Situ Hybridization | 1 | 2007 | 201 | 0.070 |
Why?
|
| Coloring Agents | 1 | 2007 | 66 | 0.070 |
Why?
|
| Luciferases | 1 | 2007 | 105 | 0.070 |
Why?
|
| Baculoviral IAP Repeat-Containing 3 Protein | 1 | 2007 | 4 | 0.070 |
Why?
|
| Cancer Vaccines | 1 | 2007 | 61 | 0.070 |
Why?
|
| Plant Oils | 1 | 2007 | 31 | 0.070 |
Why?
|
| Genes, Reporter | 1 | 2007 | 191 | 0.070 |
Why?
|
| Biomarkers | 4 | 2021 | 1593 | 0.070 |
Why?
|
| Cyclooxygenase 2 | 3 | 2012 | 160 | 0.070 |
Why?
|
| Catheterization | 1 | 2007 | 209 | 0.070 |
Why?
|
| Neutrophils | 1 | 2007 | 204 | 0.070 |
Why?
|
| Receptor, Melatonin, MT1 | 3 | 2012 | 10 | 0.070 |
Why?
|
| Receptor, Melatonin, MT2 | 3 | 2012 | 11 | 0.070 |
Why?
|
| Staining and Labeling | 1 | 2006 | 144 | 0.070 |
Why?
|
| Histocompatibility Antigens Class II | 1 | 2006 | 77 | 0.070 |
Why?
|
| Infant | 1 | 2012 | 2891 | 0.070 |
Why?
|
| Myelitis | 1 | 2005 | 9 | 0.070 |
Why?
|
| Avian Proteins | 1 | 2004 | 23 | 0.060 |
Why?
|
| Female | 6 | 2016 | 38074 | 0.060 |
Why?
|
| Antigens, Surface | 1 | 2004 | 71 | 0.060 |
Why?
|
| Electrophysiology | 1 | 2004 | 160 | 0.060 |
Why?
|
| Blood Proteins | 1 | 2004 | 94 | 0.060 |
Why?
|
| Nucleosomes | 1 | 2003 | 25 | 0.060 |
Why?
|
| Time Factors | 6 | 2009 | 4655 | 0.060 |
Why?
|
| Oligodendroglia | 2 | 2017 | 107 | 0.060 |
Why?
|
| Antigens, CD | 1 | 2004 | 230 | 0.050 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 2003 | 137 | 0.050 |
Why?
|
| Isoenzymes | 1 | 2003 | 308 | 0.050 |
Why?
|
| Glioma | 1 | 2003 | 140 | 0.050 |
Why?
|
| Forecasting | 1 | 2003 | 277 | 0.050 |
Why?
|
| Child | 1 | 2012 | 6405 | 0.050 |
Why?
|
| Autophagy-Related Proteins | 1 | 2021 | 17 | 0.050 |
Why?
|
| Cerebral Cortex | 1 | 2004 | 415 | 0.050 |
Why?
|
| Phenols | 2 | 2010 | 73 | 0.050 |
Why?
|
| Pyrazoles | 2 | 2010 | 190 | 0.040 |
Why?
|
| Mice, Inbred C57BL | 4 | 2008 | 2791 | 0.040 |
Why?
|
| Chronic Disease | 2 | 2016 | 1330 | 0.040 |
Why?
|
| Boron Compounds | 2 | 2009 | 21 | 0.040 |
Why?
|
| Nystagmus, Optokinetic | 1 | 2016 | 5 | 0.040 |
Why?
|
| Acute Disease | 2 | 2011 | 658 | 0.040 |
Why?
|
| Statistics, Nonparametric | 2 | 2009 | 306 | 0.040 |
Why?
|
| Primary Cell Culture | 1 | 2016 | 56 | 0.030 |
Why?
|
| Fura-2 | 2 | 2009 | 21 | 0.030 |
Why?
|
| Electroretinography | 1 | 2016 | 122 | 0.030 |
Why?
|
| Hydrogen Peroxide | 2 | 2010 | 168 | 0.030 |
Why?
|
| Neurofilament Proteins | 2 | 2006 | 20 | 0.030 |
Why?
|
| Cycloaddition Reaction | 1 | 2016 | 6 | 0.030 |
Why?
|
| Photic Stimulation | 1 | 2016 | 229 | 0.030 |
Why?
|
| Catalysis | 1 | 2016 | 123 | 0.030 |
Why?
|
| Calcium Signaling | 2 | 2007 | 97 | 0.030 |
Why?
|
| Th17 Cells | 1 | 2016 | 116 | 0.030 |
Why?
|
| Visual Acuity | 1 | 2016 | 236 | 0.030 |
Why?
|
| Ligands | 1 | 2016 | 317 | 0.030 |
Why?
|
| Copper | 1 | 2016 | 149 | 0.030 |
Why?
|
| Tumor Microenvironment | 1 | 2015 | 213 | 0.030 |
Why?
|
| Antioxidants | 2 | 2008 | 304 | 0.030 |
Why?
|
| Cell Count | 2 | 2004 | 248 | 0.030 |
Why?
|
| Aquaporin 4 | 1 | 2012 | 3 | 0.030 |
Why?
|
| Mice, SCID | 1 | 2013 | 238 | 0.030 |
Why?
|
| Drug Discovery | 1 | 2013 | 94 | 0.030 |
Why?
|
| Calbindins | 1 | 2012 | 23 | 0.030 |
Why?
|
| Molecular Structure | 1 | 2013 | 397 | 0.030 |
Why?
|
| Parvalbumins | 1 | 2012 | 29 | 0.030 |
Why?
|
| Mossy Fibers, Hippocampal | 1 | 2012 | 4 | 0.030 |
Why?
|
| Adenosine Kinase | 1 | 2012 | 6 | 0.030 |
Why?
|
| Computer Simulation | 1 | 2016 | 706 | 0.030 |
Why?
|
| Cell Cycle Checkpoints | 1 | 2012 | 37 | 0.030 |
Why?
|
| DNA Modification Methylases | 1 | 2012 | 24 | 0.030 |
Why?
|
| DNA Repair Enzymes | 1 | 2012 | 53 | 0.020 |
Why?
|
| Hypoxia-Inducible Factor 1, alpha Subunit | 1 | 2012 | 71 | 0.020 |
Why?
|
| Sympathetic Nervous System | 1 | 2011 | 81 | 0.020 |
Why?
|
| Comprehension | 1 | 2012 | 71 | 0.020 |
Why?
|
| Primates | 1 | 2011 | 14 | 0.020 |
Why?
|
| Injections, Intraperitoneal | 1 | 2011 | 89 | 0.020 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2012 | 507 | 0.020 |
Why?
|
| Myositis | 1 | 2011 | 24 | 0.020 |
Why?
|
| ATP-Binding Cassette Transporters | 1 | 2012 | 120 | 0.020 |
Why?
|
| DNA Repair | 1 | 2012 | 127 | 0.020 |
Why?
|
| Estrogen Antagonists | 1 | 2010 | 10 | 0.020 |
Why?
|
| Histocompatibility Antigens Class I | 1 | 2011 | 24 | 0.020 |
Why?
|
| Hybrid Cells | 1 | 2010 | 18 | 0.020 |
Why?
|
| Tissue Embedding | 1 | 2010 | 4 | 0.020 |
Why?
|
| Receptors, G-Protein-Coupled | 1 | 2012 | 167 | 0.020 |
Why?
|
| Flavoproteins | 1 | 2010 | 4 | 0.020 |
Why?
|
| Dogs | 1 | 2011 | 490 | 0.020 |
Why?
|
| Tryptamines | 1 | 2010 | 7 | 0.020 |
Why?
|
| Embryo, Mammalian | 1 | 2010 | 176 | 0.020 |
Why?
|
| Nerve Fibers, Myelinated | 1 | 2010 | 49 | 0.020 |
Why?
|
| Extracellular Signal-Regulated MAP Kinases | 1 | 2010 | 175 | 0.020 |
Why?
|
| L-Lactate Dehydrogenase | 1 | 2009 | 67 | 0.020 |
Why?
|
| Electric Capacitance | 1 | 2009 | 8 | 0.020 |
Why?
|
| Calcium Channel Agonists | 1 | 2009 | 18 | 0.020 |
Why?
|
| Cell Physiological Phenomena | 1 | 2009 | 19 | 0.020 |
Why?
|
| Intracellular Space | 1 | 2009 | 42 | 0.020 |
Why?
|
| Jurkat Cells | 1 | 2009 | 59 | 0.020 |
Why?
|
| Receptor, Cannabinoid, CB2 | 1 | 2009 | 27 | 0.020 |
Why?
|
| Clinical Trials as Topic | 1 | 2013 | 848 | 0.020 |
Why?
|
| Uncoupling Agents | 1 | 2008 | 10 | 0.020 |
Why?
|
| Rotenone | 1 | 2008 | 10 | 0.020 |
Why?
|
| Neurotoxins | 1 | 2008 | 30 | 0.020 |
Why?
|
| Time | 1 | 2008 | 57 | 0.020 |
Why?
|
| Chemokine CCL2 | 1 | 2009 | 101 | 0.020 |
Why?
|
| Receptor, Cannabinoid, CB1 | 1 | 2009 | 68 | 0.020 |
Why?
|
| Cannabinoids | 1 | 2009 | 90 | 0.020 |
Why?
|
| Necrosis | 1 | 2008 | 239 | 0.020 |
Why?
|
| Liver | 1 | 2013 | 1118 | 0.020 |
Why?
|
| Aging | 1 | 2013 | 911 | 0.020 |
Why?
|
| Th2 Cells | 1 | 2007 | 48 | 0.020 |
Why?
|
| Dopamine Plasma Membrane Transport Proteins | 1 | 2007 | 82 | 0.020 |
Why?
|
| Lumbar Vertebrae | 1 | 2007 | 112 | 0.020 |
Why?
|
| Laminectomy | 1 | 2006 | 13 | 0.020 |
Why?
|
| Macrophages | 1 | 2010 | 647 | 0.020 |
Why?
|
| Central Nervous System Depressants | 1 | 2007 | 182 | 0.020 |
Why?
|
| Corpus Striatum | 1 | 2007 | 279 | 0.020 |
Why?
|
| Fluorescent Antibody Technique, Indirect | 1 | 2005 | 95 | 0.020 |
Why?
|
| Edema | 1 | 2005 | 66 | 0.020 |
Why?
|
| Electrophoresis, Polyacrylamide Gel | 1 | 2005 | 272 | 0.020 |
Why?
|
| Recurrence | 1 | 2007 | 948 | 0.020 |
Why?
|
| Sodium Channels | 1 | 2004 | 24 | 0.010 |
Why?
|
| Hydrolysis | 1 | 2004 | 144 | 0.010 |
Why?
|
| Oligonucleotides, Antisense | 1 | 2004 | 48 | 0.010 |
Why?
|
| Receptors, Kainic Acid | 1 | 2004 | 24 | 0.010 |
Why?
|
| Basigin | 1 | 2004 | 53 | 0.010 |
Why?
|
| Inflammation Mediators | 1 | 2005 | 244 | 0.010 |
Why?
|
| Cytochrome c Group | 1 | 2003 | 22 | 0.010 |
Why?
|
| Neuroglia | 1 | 2004 | 136 | 0.010 |
Why?
|
| Tetrazolium Salts | 1 | 2003 | 36 | 0.010 |
Why?
|
| Animals, Newborn | 1 | 2004 | 396 | 0.010 |
Why?
|
| Microscopy, Electron | 1 | 2003 | 351 | 0.010 |
Why?
|
| Cytoplasm | 1 | 2003 | 155 | 0.010 |
Why?
|
| Thiazoles | 1 | 2003 | 95 | 0.010 |
Why?
|
| Receptors, N-Methyl-D-Aspartate | 1 | 2004 | 266 | 0.010 |
Why?
|
| Membrane Glycoproteins | 1 | 2004 | 370 | 0.010 |
Why?
|
| Peptide Fragments | 1 | 2003 | 483 | 0.010 |
Why?
|
| United States | 1 | 2013 | 7367 | 0.010 |
Why?
|
| Carrier Proteins | 1 | 2003 | 597 | 0.010 |
Why?
|
| Age Factors | 1 | 2004 | 1864 | 0.010 |
Why?
|